Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Clinical Pharmacist-Led Cardiovascular Risk Assessment in Patients With Chronic Kidney Disease (CRICKD)

A legfontosabb adatok

Ki végzi
Marmara University
Hol
Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
150 fő vett részt
Kezdés
2022. jan. 3.
Befejezés
2024. márc. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Clinical Pharmacist-Led Pharmaceutical Care
  • Standard Medical Care (SMC)
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év – 74 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (6)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Adults aged 18-74 years
  • Patients diagnosed with chronic kidney disease (CKD), including those receiving dialysis
  • Patients hospitalised in the internal medicine clinic
  • Patients who agreed to participate in the study

Ki nem vehet részt

  • Patients with dementia or Alzheimer's disease
  • Patients who did not agree to participate in the study

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Chronic kidney disease (CKD) is a long-term condition that can increase the risk of cardiovascular diseases, such as heart attacks and strokes. People with CKD often have other health conditions and take several medications, which can make following treatment plans challenging. Clinical pharmacists may help these patients by reviewing their medications, providing education, and supporting medication adherence and cardiovascular risk management.

A teljes eredeti leírásKevesebb

This study evaluated the impact of a clinical pharmacist-led pharmaceutical care program on cardiovascular risk, medication adherence, and quality of life in hospitalized adults with CKD.

The study was conducted at a research and training hospital in Istanbul, Türkiye, with a planned six-month follow-up. A total of 150 patients were initially enrolled and assigned to either an intervention group or a control group. Due to deaths, withdrawal from the study, and loss to follow-up, 101 patients were included in the final analysis.

Patients in the control group received standard medical care. Patients in the intervention group received additional pharmaceutical care from a clinical pharmacist, including medication review, education about CKD and cardiovascular risk factors, counseling on medication adherence and lifestyle changes, and follow-up counseling.

The study assessed cardiovascular risk using a Framingham-based risk model. Medication adherence and health-related quality of life were evaluated using standardized questionnaires. Medication regimen complexity and relevant clinical measurements were also assessed.

The findings showed that cardiovascular risk scores decreased in both groups during the study period. Medication adherence increased in both groups, from 59.2% to 75.5% in the control group and from 75.0% to 88.5% in the intervention group. However, the difference in medication adherence between the groups at follow-up was not statistically significant. Quality-of-life scores were significantly higher in the intervention group at both baseline and follow-up. A weak negative correlation was observed between medication regimen complexity and quality of life, indicating that greater medication complexity was associated with lower quality-of-life scores.

Overall, the findings suggest that clinical pharmacist-led pharmaceutical care may support medication management in patients with CKD. However, the study did not demonstrate statistically significant differences between groups in medication adherence or cardiovascular risk outcomes. Further studies with larger samples and adequate follow-up are needed to clarify the effects of pharmacist-led interventions in this population.

A vizsgálat 2 csoportja

  • Clinical Pharmacist-Led Pharmaceutical CareA vizsgált kezelés

    Participants in this group received standard medical care in addition to a clinical pharmacist-led pharmaceutical care program. The intervention included medication review, education about chronic kidney disease and cardiovascular risk factors, counselling on medication adherence, and advice on lifestyle modifications, including dietary recommendations and smoking cessation. Follow-up counselling was provided during the six-month study period.

  • Standard Medical Care (Control Group)A vizsgált kezelés

    Participants in this group received standard medical care without the additional clinical pharmacist-led pharmaceutical care programme.

    Kezelés: Standard Medical Care (SMC)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Impact of Clinical Pharmacist-Led Cardiovascular Risk Assessment on Medication Adherence and Quality of Life in Patients With Chronic Kidney Disease: A Randomised Controlled Study
A regiszteradat frissítve
2026. november 12.